• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    10x Genomics (TXG) Could Be 27% Below Fair Value On Raised 2026 Guidance

    Simply Wall St·09/05/2026 02:25:25
    Listen to the news

    10x Genomics (TXG) has drawn fresh attention after management raised its 2026 revenue guidance to a range of US$610 million to US$630 million. This reflects confidence in consumables demand and the Atera product line.

    10x Genomics has seen strong momentum build over 2024, with a 30-day share price return of 32.01% and a 90-day share price return of 101.84% helping lift the stock to US$62.65. The 1-year total shareholder return of 348.78% contrasts with a 5-year total shareholder return that is still down 66.04%.

    Compare 10x Genomics' guidance driven momentum with a hand picked group of other high growth opportunities using the 19 high quality undiscovered gems.

    10x Genomics now has guidance that points to a solid revenue base and a stock that has rapidly re-rated. The next step is to see whether that story supports the current US$62.65 share price.

    Most Popular Narrative: 26.5% Overvalued

    The most followed narrative on 10x Genomics puts fair value at $49.54, which sits below the latest $62.65 close and frames a demanding setup for the stock.

    Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.

    Read the complete narrative. Read the complete narrative.

    Want to see how this consumables engine feeds into the valuation? The narrative leans on sustained revenue growth, higher margins and a rich future earnings multiple. The exact mix might surprise you.

    The same narrative also leans on updated assumptions around future revenue expansion, improving profit margins and a higher future P/E multiple, all discounted back using a 7.93% rate. Analysts in that narrative aggregate to a fair value of $49.54, which is above the $49.54 consensus price target cited and below the current $62.65 share price, pointing to a gap between modeled fundamentals and what the market is currently willing to pay.

    Result: Fair Value of $49.54 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear risks for 10x Genomics, including pressure on research budgets and lower instrument pricing. These factors could quickly challenge this upbeat narrative.

    Find out about the key risks to this 10x Genomics narrative.

    Next Steps

    With sentiment around 10x Genomics clearly mixed, it may be helpful to quickly review the full picture for yourself so you can decide where you stand. You can weigh both sides of the story by checking the 1 key reward and 3 important warning signs.

    Looking for more 10x Genomics style investment ideas?

    If 10x Genomics has caught your attention, do not stop here. Use the Simply Wall St Screener to uncover fresh stock ideas before the crowd notices.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.